Effect of Problem-Oriented Evidence-Based Nursing on Clinical Recovery and Prognosis in Patients with Arrhythmia after Acute Myocardial Infarction.

Background: To probe into the influence of evidence-based nursing (EBN) on clinical recovery and prognosis of patients with arrhythmia after acute myocardial infarction (AMI). Methods: Totally, 240 AMI patients with arrhythmia treated in Taizhou People's Hospital (Jiangsu, China) from July 2019 to December 2020 were collected and randomly divided into the study group (n = 120) and control group (n = 120). The control group was received routine nursing, while the study group carried out EBN. The following indicators were evaluated and compared between the two groups: length of hospital stay, symptom disappearance time, cardiac function, psychological status, and incidence of adverse events after 6 months of follow-up were. Results: Compared to the control group, the length of hospital stay, symptom disappearance time, LVEF (left ventricular ejection fraction), LVEDD (left ventricular end-diastolic diameter), SAS (self-rating anxiety scale) score and SDS (self-rating depression scale) score in the study group were significant improves (P < 0.05), and the incidence of adverse events after 6-month follow-up in the study group was also significantly lower than that in the control group (P < 0.05). Conclusion: EBN intervention for AMI patients with arrhythmia can significantly improve the length of hospital stay and symptom disappearance time, adjust cardiac function and psychological status, and reduce the incidence of adverse events.

[Determination of recombinant hirudin in urine of rat by spectrophotometric method].

To develop a spectrophotometric method for determining the concentration of recombinant hirudin (rH) in urine of rats. rH concentration was determined based on the rH inhibility to thrombin which hydrolyzed the Chromozym TH TH chromogenic substrate to form the specific pNA absorbed at 405 nm. The standard rH in rat urine was determined by the spectrophotometric method at concentration of 6.25 to 75 ng x mL(-1) with day and intra-day RSD < 10%, method recoveries of > 95% and the dilution recoveries of > 93%. The rH samples of rat urines which iv dose of 0.5, 1.0, and 2.0 mg x kg(-1) were collected and analyzed by the CSA method. Their cumulative excretion rH at 0-12 hr were (116.850 +/- 57.160), (235.544 +/- 39.375) and (474.986 +/- 85.426) microg x kg(-1). The calculated cumulative excretion rate of three doses is about 23% which indicates that the rH was eliminated in the way of a linear kinetics in rats. The rH content in rat urine could be measured by the spectrophotometric method accurately, reliably and sensitively for the rH urinary excretion dynamics study.

Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays.

AIM: To compare the analytical methods used to study the pharmacokinetics of recombinant hirudin in the plasma of rats that had been injected with (125)I-recombinant hirudin. METHODS: 2.0 mg/kg (125)I-recombinant hirudin were injected intravenously into rats. The recombinant hirudins in the plasma was analyzed by chromogenic substrate assay, enzyme-linked immunosorbent assay (ELISA), total radioisotope assay (RA) and trichloroacetic acid pre-treated total radioisotope assay (TCA-RA). RESULTS: The chromogenic substrate assay standard curve was linear over the concentration range from 3.12 to 40.00 ng/ml for the recombinant hirudin in plasma. The relative standard deviations (RSD) for the intra- and inter-day variation were 5.0 to 6.3% and 11.9 to 12.6%, respectively. The recoveries of recombinant hirudin was 89.8% to 100.7%. The limit of quantification (LOQ) was 3.12 ng/ml. The concentration-time curve of the recombinant hirudin in the plasma could be explained as a two-compartment model. Pharmacokinetic parameters, including the half-life of distribution phase (t1/2 α), the half-life of elimination phase (t1/2 ß), volume of apparent distribution (Vd), and area under the concentration-time curve from zero to infinite time (AUC0-t) were 7.59 min, 46.99 min, 0.17 L/kg, and 204.5 mg/L/min, respectively, as determined by chromogenic substrate assay; 6.41 min, 47.28 min, 1.24 L/kg, and 575.18 mg/L/min, respectively, as determined by ELISA; 3.69 min, 701.90 min, 0.04 L/kg, and 4189 mg/L/min, respectively as determined by RA; and 4.57 min, 724.9 min, 0.09 L/kg, and 2329 mg/L/min, respectively, as determined by TCA-RA. CONCLUSIONS: The chromogenic substrate assay on the concentration dynamics of the recombinant hirudin in the plasma is a specific, sensitive, and accurate analytical method for pharmacokinetic studies. Moreover, the pharmacokinetic parameters determined by the chromogenic substrate assay and ELISA are congruent except for AUC.